# A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS

> **NCT05959850** · PHASE2 · UNKNOWN · sponsor: **The Florey Institute of Neuroscience and Mental Health** · enrollment: 50 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Ambroxol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05959850
- **Lead sponsor:** The Florey Institute of Neuroscience and Mental Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-13
- **Primary completion:** 2024-06
- **Final completion:** 2024-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05959850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05959850, "A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05959850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*